Abstract: A process for the preparation of compounds of formula (I), wherein R is C2-C20 linear or branched alkyl, C3-C7 cycloalkyl, phenyl or benzyl, which can optionally be substituted by C1-C4 alkyl, halogen or C1-C4 alkoxy group, said process comprising: a) oxidation of eserine with hydrogen peroxide in the presence of a base and subsequent hydrolysis to geneseroline, without isolating the intermediate geneserine; b) acylation of geneseroline with an isocyanate of formula R—N═C═O, wherein R is as defined above, in the presence of a basic catalyst; c) optional transformation into a pharmaceutically acceptable salt. Compounds of formula (I) wherein R is a phenyl or benzyl, which can be optionally substituted by alkyl, halogen or alkoxy, are selective, potent brain anticholinesterase inhibitors.

Abstract: A process, and variations thereof, for the preparation of 5,6-dihydroxy-2-amino-1,2,3,4-tetrahydronaphthalene derivatives of formula (I), wherein R.sub.1, R.sub.2, R.sub.3 can independently be hydrogen or lower alkyl.

Abstract: A process, and variations thereof, for the preparation of 5,6-dihydroxy-2-amino-1,2,3,4-tetrahydronaphthalene derivatives of formula (I), wherein R.sub.1, R.sub.2, R.sub.3 can independently be hydrogen or lower alkyl.

Abstract: A process, and variations thereof, for the preparation of 5,6-dihydroxy-2-amino-1,2,3,4-tetrahydronaphthalene derivatives of formula (I), wherein R.sub.1, R.sub.2, R.sub.3 can independently be hydrogen or lower alkyl.

Abstract: A process for purifying natural pulmonary surfactant by dispersing animal lung tissue on an inert carrier and extracting with a supercritical fluid.

Abstract: Geneserine homologs of formula I ##STR1## in which R is a straight or branched C.sub.2 -C.sub.20 alkyl group, a C.sub.3 -C.sub.7 cycloalkyl group, an unsubstituted phenyl or benzyl group, or a phenyl or benzyl group substituted by a C.sub.1 -C.sub.4 alkyl group, a halogen atom or a C.sub.1 -C.sub.4 alkoxy group, or a salt with an organic or inorganic non-toxic acid, exhibit anticholinesterase activity and may be useful in the treatment of Alzheimer disease and other conditions due to a neurological deficiency.

Abstract: 2-Propyl-2-pentanoic acid (valproic acid) esters and (E)-2-propyl-2-pentenoic acid [(E)-2-valproenoic acid] esters surprisingly proved to have valuable properties, in that they show anticonvulsive and antiepileptic activities comparable with those of valproic acid, as well as an improved bioavailability and a markedly reduced toxicity.

Abstract: 5,6-Dimethoxy-2-[2-(4-hydroxyphenyl)-2-hydroxy-2-methylethyl]amino- 1,2,3,4-tetrahydronaphthalene has inotropic and vasodilating activities and therefore can be used in the treatment of cardiocirculatory failure. The compound can be in the form of a single stereoisomer or as a mixture of two or more stereoisomers.

Abstract: Compounds of the formulaHet-S(O).sub.n -CH.sub.2 -A (I)wherein Het is a substituted imidazolyl, purinyl, thieno-imidazolyl or imidazo-pyridyl group, n is 0 or 1, A is one of the following structures: ##STR1## and their physiologically acceptable salts have antiulcer and gastric acid antisecretory activity.

Abstract: Imidazo[4,5-c] pyridine compounds and physiologically acceptable salts thereof having antiulcer and gastric acid antisecretory activities and pharmaceutical compositions containing them.

Abstract: Isosorbide 2- and 5-mononitrate esters with aliphatic, aryl, or cynnamic acids or diacids, or with alkylcarbonyloxy substituents optionally containing an isosorbide 2- or 5-mononitrate group, are useful in human therapy.

Abstract: Compounds of formula I ##STR1## wherein A represents: a saturated or unsaturated acyclic residue;a saturated cyclic or heterocyclic residue;a saturated or unsaturated bicyclic residue; and R represents OH, a C.sub.1 -C.sub.4 alkoxy group or a straight or heterocycle aminoresidue; R.sub.1 represents hydrogen, an alkyl group or an aromatic or heteroaromatic residue.Compounds I are endowed with valuable therapeutic characteristics.

Abstract: Compounds of formula I ##STR1## wherein A represents: a saturated cyclic or heterocyclic aromatic or heteroaromatic residue;a saturated or unsaturated bicyclic residue; and R represents H, an alkyl, cycloalkyl or alkoxyalkyl group.Compounds I are endowed with valuable therapeutic characteristics.

Abstract: New inclusion compounds of 4-hydroxy-2-methyl-N-2-pyridyl-2H-1,2-benzothiazine-3-carboxyamide-1,1-dio xide with .alpha., .beta. or .gamma. cyclodextrins, obtained by reaction of said cyclodextrins and said 4-hydroxy-2-methyl-N-2-pyridyl-2H-1,2-benzothiazine-3-carboxyamide-1,1-dio xide in aqueous or water/organic solutions are described. The ratio between 4-hydroxy-2-methyl-N-2-pyridyl-2H-1,2-benzothiazine-1,1-dioxide and the cyclodextrins is comprised between 1:10 and 1:1; preferably, it is about 1:2.5.The compounds of the invention possess high antiinflammatory and analgesic activities, together with a considerably reduced gastrolesive action.